**Calibration analysis references**

Alarid-Escudero F, Knudsen AB, Ozik J, Collier N, Kuntz KM. Characterization and valuation of uncertainty of calibrated parameters in stochastic decision models. ArXiv Prepr ArXiv190604668 2019.

<https://arxiv.org/abs/1906.04668>

Alarid-Escudero, F., MacLehose, R. F., Peralta, Y., Kuntz, K. M., Enns, E. A. (2018). Non-identifiability in Model Calibration and Implications for Medical Decision Making. Medical Decision Making, 38(7), 810-821.

<https://www.ncbi.nlm.nih.gov/pubmed/30248276>

Enns, E. A., Kao, S. Y., Kozhimannil, K. B., Kahn, J., Farris, J., & Kulasingam, S. L. (2017). Using Multiple Outcomes of Sexual Behavior to Provide Insights into Chlamydia Transmission and the Effectiveness of Prevention Interventions in Adolescents. Sexually Transmitted Diseases, 44(10), 1–8.

<https://journals.lww.com/stdjournal/fulltext/2017/10000/Using_Multiple_Outcomes_of_Sexual_Behavior_to.8.aspx>

Menzies, N. A., Soeteman, D. I., Pandya, A., & Kim, J. J. (2017). Bayesian Methods for Calibrating Health Policy Models: A Tutorial. PharmacoEconomics, 35(6), 613–624.

<https://www.ncbi.nlm.nih.gov/pubmed/28247184>

Enns, E. A., Cipriano, L. E., Simons, C. T., & Kong, C. Y. (2014). Identifying Best-Fitting Inputs in Health-Economic Model Calibration. Medical Decision Making, 35(2), 170–182.

<https://www.ncbi.nlm.nih.gov/pubmed/24799456>

Stout, N. K., Knudsen, A. B., Kong, C. Y., McMahon, P. M., & Gazelle, G. S. (2009). Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines. PharmacoEconomics, 27(7), 533–545.

<https://www.ncbi.nlm.nih.gov/pubmed/19663525>

Vanni, T., Karnon, J., Madan, J., White, R. G., Edmunds, W. J., Foss, A. M., & Legood, R. (2011). Calibrating Models in Economic Evaluation: A Seven-Step Approach. PharmacoEconomics, 29(1), 35–49.ç

<https://link.springer.com/article/10.2165%2F11584600-000000000-00000>

Karnon, J., & Vanni, T. (2011). Calibrating Models in Economic Evaluation: A Comparison of Alternative Measures of Goodness of Fit, Parameter Search Strategies and Convergence Criteria. PharmacoEconomics, 29(1), 51–62.

<https://link.springer.com/article/10.2165%2F11584610-000000000-00000>

**Parameter estimation**

van de Kassteele, J., Hoogenveen, R. T., Engelfriet, P. M., van Baal, P. H. M., & Boshuizen, H. C. (2012). Estimating net transition probabilities from cross-sectional data with application to risk factors in chronic disease modeling. Statistics in Medicine, 31(6), 533–543.

<https://doi.org/10.1002/sim.4423>

Williams, C., Lewsey, J. D., Briggs, A. H., & Mackay, D. F. (2016). Cost-Effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. Medical Decision Making, 1–13.

<https://doi.org/10.1177/0272989X16651869>

Williams, C., Lewsey, J. D., Mackay, D. F., & Briggs, A. H. (2016). Estimation of Survival Probabilities for Use in Cost-Effectiveness Analyses: A Comparison of a Multi-State Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling. Medical Decision Making, 1–13.

<https://doi.org/10.1177/0272989X16670617>

Welton, N. J., & Ades, A. E. (2005). Estimation of Markov Chain Transition Probabilities and Rates from Fully and Partially Observed Data: Uncertainty Propagation, Evidence Synthesis, and Model Calibration. Medical Decision Making, 25(6), 633–645.

<https://www.ncbi.nlm.nih.gov/pubmed/16282214>

**Value of Information Analysis**

Jutkowitz, E., Alarid-Escudero, F., Choi, H. K., Kuntz, K. M., & Jalal, H. (2017). Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. PharmacoEconomics, 35(10), 1073–1085.

<https://www.ncbi.nlm.nih.gov/pubmed/28631197>

Jalal, H., & Alarid-Escudero, F. (2018). A Gaussian Approximation Approach for Value of Information Analysis. Medical Decision Making, 38(2), 174–188.

https://www.ncbi.nlm.nih.gov/pubmed/28735563

Alarid-Escudero F, Enns EA, Kuntz KM, Michaud TL, Jalal H. “Time Traveling Is Just Too Dangerous” But Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. Value Health 2019;22:611–8. doi:10.1016/j.jval.2019.02.008.

<https://www.valueinhealthjournal.com/article/S1098-3015(19)30133-0>

Jutkowitz E, Alarid-Escudero F, Kuntz KM, Jalal H. The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis. Pharmacoeconomics 2019;37:871–877. doi:10.1007/s40273-019-00770-z.

<http://link.springer.com/10.1007/s40273-019-00770-z>